May 2012
Government agency cautions against hormone replacement therapy
- Thu, 05/31/2012 - 1:40pm
In 2009, the U.S.
EMA recommends updated Pradaxa labels
- Tue, 05/29/2012 - 2:04pm
Study compares dabigatran to warfarin in VTE treatment
- Tue, 05/29/2012 - 11:06am
A study conducted primarily by Boehringer Ingelheim, the maker of Pradaxa, suggests a fixed dose of dabigatran therapy
Take Fosamax and other bisphosphonates for 5+ years and break your thigh bone
- Thu, 05/24/2012 - 11:58am
Bisphosphonate drugs like Fosamax, Reclast, Actonel, and Boniva have been around since the 1990s, but researchers recently questioned how long they should be used.
Nexavar fails to meet endpoint goal in phase III study
- Wed, 05/23/2012 - 1:05pm
German pharmaceutical giant Bayer AG and Onyx Pharmaceuticals, Inc., announced Tuesday that Nexavar, a drug approved to treat liver and kidney cancer, failed to meet its endpoint goal in a Phase II
Takeda Pharmaceuticals determined to gain FDA drug approval
- Mon, 05/14/2012 - 1:48pm
In a country bulging with 23 million people with type 2 diabetes, Avandia and its successor, Actos, were once blockbuster drugs in the U.S.
Canada adds heart warnings to Lexapro labels
- Mon, 05/07/2012 - 4:09pm
Serotonin reuptake inhibitor Lexapro, or Cipralex, as it’s marketed in Canada, may cause heart rhythm problems. According to Health Canada, risk increases as dosage increases.
Study shows lingering side effects with breast cancer treatment
- Mon, 05/07/2012 - 3:13pm
A University of Pennsylvania research study revealed that 60 percent of breast cancer patients suffered at least one side effect up to six years after completing treatment and 30 percent experience
FDA issues warning to sports supplement drink manufacturers
- Fri, 05/04/2012 - 4:48pm